Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 18, 2012, Pages 8128-8136

  Qian, Keduo ^a   Bori, Ibrahim D ^a   Chen, Chin Ho ^b   Huang, Li ^b   Lee, Kuo Hsiung ^a,c  

^a University of North Carolina   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 (2 (2 HYDROXYETHOXY)ETHOXY)ETHOXY)ETHYL 3 BETA HYDROXYLUP 20(29) EN 28 OATE; 2 (2 (2 (2 O TERT BUTYLDIMETHYLSILYLETHOXY)ETHOXY)ETHOXY) ETHYL 3 BETA HYDROXYLUP 20(29) EN 28 OATE; 3 BETA METHOXYETHOXYMETHOXYBETULINIC ACID; 3 BETA METHOXYMETHOXYBETULINIC ACID; 3' PHENYLPROPYL 3 BETA HYDROXYLUP 20(29) EN 28 OATE; BEVIRIMAT; ETHYL O [3 BETA HYDROXYLUP 20(29) EN 28 OYL] 6 HEXANOATE; ETHYL O [3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20(29) EN 28 OYL] 6 HEXANOATE; HEXYL 3 BETA HYDROXYLUP 20(29) EN 28 OATE; HEXYL 3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20(29) EN 28 OATE; METHOXYETHOXYMETHYL 3 BETA HYDROXYLUP 20(29) EN 28 OATE; METHOXYETHOXYMETHYL 3 BETA METHOXYETHOXYMETHOXYLUP 20(29) EN 28 OATE; METHOXYETHOXYMETHYL 3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20(29) EN 28 OATE; METHOXYMETHYL 3 BETA HYDROXYLUP 20(29) EN 28 OATE; METHOXYMETHYL 3 BETA METHOXYMETHOXYLUP 20(29) EN 28 OATE; METHOXYMETHYL 3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20(29) EN 28 OATE; METHYL N [3 BETA ACETOXYLUP 20(29) EN 28 OYL] 4 PIPERAZINEBUTANOATE; METHYL N [3 BETA ACETOXYLUP 20(29) EN 28 OYL] 5 PIPERAZINEPENTANOATE; N [3 BETA HYDROXYLUP 20(29) EN 28 OYL] 4 PIPERAZINEBUTYRIC ACID; N [3 BETA HYDROXYLUP 20(29) EN 28 OYL] 5 PIPERAZINEPENTANOIC ACID; N SUCCINIMIDE 3 BETA HYDROXYLUP 20(29) EN 28 OATE; N SUCCINIMIDE 3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20(29) EN 28 OATE; OCTYL 3 BETA HYDROXYLUP 20(29) EN 28 OATE; PIPERAZINE; PIPERIDINE DERIVATIVE; PROP 2' YNYL 3 BETA HYDROXYLUP 20(29) EN 28 OATE; PROP 2' YNYL 3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20(29) EN 28 OATE; PROPYL 3 BETA HYDROXYLUP 20(29) EN 28 OATE; PROPYL 3 BETA O (3',3' DIMETHYLSUCCINYL)LUP 20(29) EN 28 OATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG DESIGN; DRUG STABILITY; HIV-1; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINATES; TRITERPENES; VIRUS REPLICATION;

EID: 84866879469     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301040s     Document Type: Article

References (28)

1. Barbaro, G.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome Curr. Pharm. Des. 2005, 11, 1805-1843
2. Ho, D. D.; Neumann, A. U.; Perelson, A. S.; Chen, W.; Leonard, J. M.; Markowitz, M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 1995, 373, 123-126
3. Hammer, S. M.; Katzenstein, D. A.; Hughes, M. D.; Gundacker, H.; Schooley, R. T.; Haubrich, R. H.; Henry, W. K.; Lederman, M. M.; Phair, J. P.; Niu, M.; Hirsch, M. S.; Merigan, T. C. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team N. Engl. J. Med. 1996, 335, 1081-1090
4. Gulick, R. M.; Meibohm, A.; Havlir, D.; Eron, J. J.; Mosley, A.; Chodakewitz, J. A.; Isaacs, R.; Gonzalez, C.; McMahon, D.; Richman, D. D.; Robertson, M.; Mellors, J. W. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine AIDS 2003, 17, 2345-2349
5. World Health Organization. Health Topics: HIV/AIDS. http://www.who.int/ topics/hiv-aids/en/ (accessed 2011).
6. Chun, T. W.; Carruth, L.; Finzi, D.; Shen, X.; DiGiuseppe, J. A.; Taylor, H.; Hermankova, M.; Chadwick, K.; Margolick, J.; Quinn, T. C.; Kuo, Y. H.; Brookmeyer, R.; Zeiger, M. A.; Barditch-Crovo, P.; Siliciano, R. F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 1997, 387, 183-188
7. Finzi, D.; Hermankova, M.; Pierson, T.; Carruth, L. M.; Buck, C.; Chaisson, R. E.; Quinn, T. C.; Chadwick, K.; Margolick, J.; Brookmeyer, R.; Gallant, J.; Markowitz, M.; Ho, D. D.; Richman, D. D.; Siliciano, R. F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 1997, 278, 1295-1300
8. Wong, J. K.; Hezareh, M.; Gunthard, H. F.; Havlir, D. V.; Ignacio, C. C.; Spina, C. A.; Richman, D. D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia Science 1997, 278, 1291-1295
9. Piscitelli, S. C.; Flexner, C.; Minor, J. R.; Polis, M. A.; Masur, H. Drug interactions in patients infected with human immunodeficiency virus Clin. Infect. Dis. 1996, 23, 685-693
10. Louie, M.; Markowitz, M. Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective Antiviral Res. 2002, 55, 15-25
11. Boden, D.; Hurley, A.; Zhang, L.; Cao, Y.; Guo, Y.; Jones, E.; Tsay, J.; Ip, J.; Farthing, C.; Limoli, K.; Parkin, N.; Markowitz, M. HIV-1 drug resistance in newly infected individuals JAMA, J. Am. Med. Assoc. 1999, 282, 1135-1141
12. Fujioka, T.; Kashiwada, Y.; Kilkuskie, R. E.; Cosentino, L. M.; Ballas, L. M.; Jiang, J. B.; Janzen, W. P.; Chen, I. S.; Lee, K. H. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids J. Nat. Prod. 1994, 57, 243-247
13. Kashiwada, Y.; Hashimoto, F.; Cosentino, L. M.; Chen, C. H.; Garrett, P. E.; Lee, K. H. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents J. Med. Chem. 1996, 39, 1016-1017
14. Kanamoto, T.; Kashiwada, Y.; Kanbara, K.; Gotoh, K.; Yoshimori, M.; Goto, T.; Sano, K.; Nakashima, H. Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation Antimicrob. Agents Chemother. 2001, 45, 1225-1230
15. Li, F.; Goila-Gaur, R.; Salzwedel, K.; Kilgore, N. R.; Reddick, M.; Matallana, C.; Castillo, A.; Zoumplis, D.; Martin, D. E.; Orenstein, J. M.; Allaway, G. P.; Freed, E. O.; Wild, C. T. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13555-13560
16. Qian, K.; Nitz, T. J.; Yu, D.; Allaway, G. P.; Morris-Natschke, S. L.; Lee, K. H. Anti-AIDS Agents 76. From Natural Product to Clinical Trials: Bevirimat, a Plant-Derived Anti-AIDS Drug. In Natural Product Chemistry for Drug Discoverys; Buss, T.; Butler, M., Eds.; Biomolecular Sciences Series; Royal Society of Chemistry: Cambridge, U.K., 2009; pp 374-391.
17. Smith, P. F.; Ogundele, A.; Forrest, A.; Wilton, J.; Salzwedel, K.; Doto, J.; Allaway, G. P.; Martin, D. E. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3- O -(3′,3′-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection Antimicrob. Agents Chemother. 2007, 51, 3574-3581
18. Martin, D. E.; Blum, R.; Doto, J.; Galbraith, H.; Ballow, C. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers Clin. Pharmacokinet. 2007, 46, 589-598
19. Martin, D. E.; Blum, R.; Wilton, J.; Doto, J.; Galbraith, H.; Burgess, G. L.; Smith, P. C.; Ballow, C. Safety and pharmacokinetics of bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers Antimicrob. Agents Chemother. 2007, 51, 3063-3066
20. http://investor.myriad.com/releasedetail.cfm?ReleaseID=360258.
21. Huang, L.; Ho, P.; Lee, K. H.; Chen, C. H. Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives Bioorg. Med. Chem. 2006, 14, 2279-2289
22. Qian, K.; Morris-Natschke, S. L.; Lee, K. H. HIV entry inhibitors and their potential in HIV therapy Med. Res. Rev. 2009, 29, 369-393
23. Qian, K.; Yu, D.; Chen, C. H.; Huang, L.; Morris-Natschke, S. L.; Nitz, T. J.; Salzwedel, K.; Reddick, M.; Allaway, G. P.; Lee, K. H. Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents J. Med. Chem. 2009, 52, 3248-3258
24. Jiang, Z. X.; Yu, Y. B. The design and synthesis of highly branched and spherically symmetric fluorinated oils and amphiles Tetrahedron 2007, 63, 3982-3988
25. Zhang, W.; Oya, S.; Kung, M. P.; Hou, C.; Maier, D. L.; Kung, H. F. F-18 polyethyleneglycol stilbenes as PET imaging agents targeting Aβ aggregates in the brain Nucl. Med. Biol. 2005, 32, 799-809
26. Zhu, C. B.; Zhu, L.; Holz-Smith, S.; Matthews, T. J.; Chen, C. H. The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012 Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 15227-15232
27. Qian, K.; Kuo, R. Y.; Chen, C. H.; Huang, L.; Morris-Natschke, S. L.; Lee, K. H. Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors J. Med. Chem. 2010, 53, 3133-3141
28. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; MacIntyre, F.; Rance, D. J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data J. Pharmacol. Exp. Ther. 1997, 283, 46-58